ArticleJournal of virology2022
The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2
Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- Unleashing the immune arsenal: development of broad spectrum multiepitope bluetongue vaccine targeting conserved T cell epitopes of structural proteins.BMC genomics · 2026Article
- Bluetongue in ruminants: Global epidemiology, pathogenesis, and advances in diagnostic and control strategies within a One Health framework.Veterinary world · 2025Review
- Heterologous DNA-Adenovirus Prime-Boost Strategy Expressing Bluetongue Virus VP2 and VP7 Proteins Protects Against Virulent Challenge.Vaccines · 2025Article
- Biomimetic Apatite Nanoparticles and Microcrystalline Tyrosine as Biocompatible Vaccine Adjuvants: Performance in a Bluetongue Virus Sheep Model.ACS applied materials & interfaces · 2025Article
- The MVA-VP2-NS1-2A-NS2-Nt vaccine candidate provides heterologous protection in sheep against bluetongue virus.Frontiers in immunology · 2025Article
- Vaccine candidates based on MVA viral vectors expressing VP2 or VP7 confer full protection against Epizootic hemorrhagic disease virus in IFNAR(-/-) mice.Journal of virology · 2024Article
- Age- and Sex-Associated Pathogenesis of Cell Culture-Passaged Kemerovo Virus in IFNARInternational journal of molecular sciences · 2024Article
- Engineering recombinant replication-competent bluetongue viruses expressing reporter genes forMicrobiology spectrum · 2024Article
- IFNAR(-/-) Mice Constitute a Suitable Animal Model for Epizootic Hemorrhagic Disease Virus Study and Vaccine Evaluation.International journal of biological sciences · 2024Article
- Immuno-informatics study identifies conserved T cell epitopes in non-structural proteins of Bluetongue virus serotypes: formulation of a computationally optimized next-generation broad-spectrum multi-epitope vaccine.Frontiers in immunology · 2024Article
- Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virus.Frontiers in immunology · 2024Article
- Epizootic Hemorrhagic Disease Virus: Current Knowledge and Emerging Perspectives.Microorganisms · 2023Review
- Increased Clinical Signs and Mortality in IFNARPathogens (Basel, Switzerland) · 2023Article
- Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance.Vaccines · 2022Review
- Live attenuated influenza A virus vaccines with modified NS1 proteins for veterinary use.Frontiers in cellular and infection microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
Bluetongue, caused by bluetongue virus (BTV), is a widespread arthropod-borne disease of ruminants that entails a recurrent threat to the primary sector of developed and developing countries. In this work, we report modified vaccinia virus Ankara (MVA) and ChAdOx1-vectored vaccines designed to simultaneously express the immunogenic NS1 protein and/or NS2-Nt, the N-terminal half of protein NS2 (NS2
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.